Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Subscribe to see FUSION ANTIBODIES PLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
FUSION ANTIBODIES PLC is a biotech company headquartered in Belfast, United Kingdom, founded in 2000. It is publicly listed (FAB) with a market capitalisation of $17.8M. Xcout tracks 7 named people at FUSION ANTIBODIES PLC, including Robert F Stoico (Director).
1 more named person on record for FUSION ANTIBODIES PLC, with roles, board committees and tenure — see the full roster →
A few of FUSION ANTIBODIES PLC's closest competitors — see the full list of competitors and alternatives →
Trans Genic Inc., a Japanese enterprise, specializes in the development, distribution, and licensing of genetically engineered animals and antibodies. Its operations are structured into two primary divisions: Drug Discovery Support Business and Investment Business. Within its Drug Discovery Support segment, the company offers a comprehensive array of services. These include the synthesis and analytical assessment of glycans (or sugar chains), alongside extensive non-clinical investigations crucial for pharmaceuticals, food products, cosmetics, and various chemical compounds. The firm conducts diverse safety evaluations for both food and pharmaceutical agents, and provides vital support for bioequivalence studies, encompassing clinical trials, pharmacokinetic measurements, and the compilation of clinical trial reports. Hospital support services are also part of its offerings. Furthermore, Trans Genic performs drug efficacy and pharmacological testing, provides strategic advisory services covering mergers & acquisitions, business restructuring, and succession planning, and undertakes contract manufacturing of items such as genetically engineered mice, antibodies, protein hypers, and expression cells. It also markets mouse models, associated products, and research reagents. Established in 1998, the company was initially known as Kumamoto Immunochemical Laboratories Inc. before rebranding as Trans Genic Inc. in April 2000. Its corporate headquarters are located in Fukuoka City, Japan.
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other international markets. Their comprehensive offerings encompass research kits, bulk enzymes, various other biological products, as well as crucial licensing and AVV manufacturing services. The company primarily caters to clients within the biotech, pharmaceutical, and contract development and manufacturing organization (CDMO) industries. Notably, the firm adopted its current name, 4basebio PLC, in July 2021, having previously been known as 4basebio UK Societas.
Almac Group is a global company that provides a range of services across the drug development lifecycle. They offer tailored solutions to support the pharmaceutical and biotechnology industries in advancing human health.
Anthem Biosciences is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) based in Bangalore, India. The company delivers a comprehensive range of scientific services dedicated to developing and manufacturing small and large molecules.
Biocytogen provides fully human antibody discovery services and preclinical contract research organization (CRO) services. The company offers genetically engineered animal models, cell lines, gene editing services, and in vivo and in vitro pharmacology studies to support biopharmaceutical research and drug development.
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about FUSION ANTIBODIES PLC? Suggest a correction
Post the link and the card appears automatically — each network fetches the image itself.